Skip to main content

Table 3 Clinical characteristics and endocrine treatment history in patients with confirmed ESR1 E380Q mutant ttDNA

From: Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients

Clinical Characteristics Before mutation analysis After mutation analysis
CT ET CT ET
ID Metastatic ER (%) Detected ESR1 mut ESR1 mut MAFs (%) Stage at diagnosis Adjuvant ET Adjuvant ET Duration (Months) DFI (Months) No. of therapies No. of therapies Cumulative Exposure (Months) Type of ET No. of therapies No. of therapies Cumulative Exposure (Months) Type of ET
M43 a 70 E380Q 21.7 I SERM 16 16 5 Adjuvant only No No No No
M50 a 80 Y537S/ E380Q 12.8/2.69 I LHRHa, SERM 48 72 4 4 40 LHRHa, SERM, AI 1 1 2 AI
  1. Abbreviations; ttDNA tumor tissue DNA, CT chemotherapy, ET endocrine therapy, ER estrogen receptor, mut mutation, MAF mutant allele frequency, SERM selective estrogen receptor modulator, LHRHa luteinizing hormone-releasing hormone agonist, DFI, disease free interval, No. number, AI aromatase inhibitor
  2. aBoth patients were deceased